Congestive Heart Failure Biomedical Engineering - URJC

Rafa Carretero, MD, PhD

Internal Medicine Department

February 18, 2025






Definition of Congestive Heart Failure (CHF)

What is CHF?

Congestive heart failure is a chronic, progressive condition where the heart is unable to pump blood effectively, leading to inadequate tissue perfusion and fluid accumulation.

- A syndrome, not a single disease.
- Can involve the **left ventricle**, **right ventricle**, or both.
- Congestive refers to fluid accumulation in the lungs, abdomen, and limbs.



Epidemiology of CHF

Global Burden


- Affects 26 million people worldwide.
- Leading cause of hospitalization in individuals >65 years old.

Prevalence

- 1-2% of the general population.
- > 10% in individuals > 70 years old.

Economic Impact

- Annual cost in the U.S.: \$30 billion.
- High costs due to hospitalizations, medications, and advanced therapies.



Why is CHF Important?

Clinical Significance

- High morbidity and mortality: 5-year survival rate is 50%.
- Significant impact on quality of life (e.g., fatigue, dyspnea, swelling).

Public Health Challenge

- Requires a multidisciplinary approach for management.
- Early diagnosis and treatment can improve outcomes.


Mechanisms of CHF

Heart Failure with Reduced Ejection Fraction (HFrEF)

- EF < 40%.
- Impaired contractility. Inability to PUMP BLOOD forward.
- Common causes: Ischemic heart disease, dilated cardiomyopathy.


Heart Failure with Preserved Ejection Fraction (HFpEF)

- EF > 50%.
- Impaired relaxation and filling. Inability to FILL. Fluid accumulation backward.
- Common causes: Hypertension, left ventricular hypertrophy.



Normal filling

Systolic Dysfunction



Filling of the enlarged ventricles

Diastolic Dysfunction



Too little blood flows into the stiff ventricles.


Compensatory Mechanisms in CHF

Compensatory Mechanisms in CHF

- Sympathetic Nervous System (SNS)
- Renin-Angiotensin-Aldosterone System (RAAS)
- Natriuretic Peptides promote vasodilation and diuresis
- Increasing heart rate and contractility.

Downsides of these mechanisms

- They cause vasoconstriction and fluid retention.
- They promote fibrosis and remodeling.



Ventricular Remodeling

Key Changes

- Myocyte hypertrophy.
- Fibrosis.
- Chambers dilation = reduced contractility
- Dysfunction of chambers = inability to pump forward

Consequences


- Worsening contractility and relaxation.
- Increased risk of arrhythmias.

Clinical Presentation of Heart Failure


Key Concepts

- CHF results from fluid overload (causing fluid accumulation)
 and reduced cardiac output (causing inadequate perfusion).
- Symptoms and signs reflect these two pathophysiological processes.

CARDIOMYOPATHY







Symptoms of Heart Failure

Dyspnea (Shortness of Breath)

- **Exertional Dyspnea**: Difficulty breathing during physical activity.
- Orthopnea: Shortness of breath when lying flat, relieved by sitting up.
- Paroxysmal Nocturnal Dyspnea (PND): Sudden episodes of severe dyspnea at night.

Symptoms of Heart Failure

Fatigue and Weakness

- Due to reduced cardiac output and poor perfusion of skeletal muscles.
- Limits daily activities.

Fluid Retention and Edema

- Peripheral Edema: Swelling in legs, ankles, and feet.
- Ascites: Fluid accumulation in the abdomen.
- Weight Gain: Rapid weight gain due to fluid retention.

Signs of Heart Failure

Pulmonary Signs

 Crackles/Rales: Heard on lung auscultation, indicating fluid in alveoli.


Cardiac Signs


- Elevated Jugular Venous Pressure (JVP): Reflects increased right atrial pressure.
- S3 Gallop: A third heart sound heard in early diastole, indicative of volume overload.

Signs of Heart Failure

Peripheral Signs

- **Pitting Edema**: Swelling in lower extremities that leaves an indentation.
- **Hepatomegaly**: Enlarged liver due to venous congestion.









Evaluation and Diagnosis: Initial Assessment

History and Physical Examination

- Detailed history: Symptoms (e.g., dyspnea, edema), risk factors (e.g., hypertension, diabetes).
- Physical exam: Elevated JVP, peripheral edema.

Basic Diagnostic Tests

- **Electrocardiogram (ECG)**: Assess for arrhythmias, ischemia, or hypertrophy.
- Complete Blood Count (CBC): Rule out anemia or infection.
- Comprehensive Metabolic Panel: Evaluate liver function, electrolytes, renal function, and thyroid function.

Advanced Cardiac Evaluation

Essential Labs

NT-proBNP: Elevated levels support the diagnosis of CHF.

Imaging Studies

- Transthoracic Echocardiogram (TTE): Assess left ventricular ejection fraction (LVEF), valvular function, and wall motion abnormalities.
- Chest X-ray: Evaluate for pulmonary vascular congestion, cardiomegaly, or pleural effusion.






Figure: Enlarged heart



Figure: Normal heart




Echocardiography (Echo)




1,205 × 6

2D (two-dimensional) ultrasound







Specialized Tests for CHF Classification

More Advanced Cardiac Evaluation

- Stress Echocardiogram: Assess for ischemia or viability.
- Exercise Treadmill Stress Test: Evaluate functional capacity and ischemia.
- Coronary Angiogram: Identify coronary artery disease in suspected ischemic cardiomyopathy.

When to Use

- When HFrEF or HFpEF classification is unclear.
- When ischemia is suspected as the underlying cause.

Treatment: General Management

Lifestyle Modifications

- Low-Sodium Diet: Reduce fluid retention.
- Regular Exercise: Improve functional capacity.
- Weight Management: Monitor for sudden weight gain (fluid retention).

Comorbidity Management

- Control hypertension, diabetes, atrial fibrillation, obesity, valvular disease, and sleep apnea.
- Improves symptoms and reduces hospitalizations.

Pharmacologic Therapy: Diuretics

Volume Overload Management

- Loop Diuretics: Furosemide, torasemide (first-line for congestion).
- **Thiazides**: Add for refractory edema.

Key Points

- Monitor electrolytes (e.g., potassium, sodium).
- Adjust doses based on symptoms and fluid status.

Advanced Pharmacologic Therapy

Neurohormonal Modulation

- **Beta-Blockers**: Carvedilol, metoprolol bisoprolol (reduce sympathetic activation).
- ACE Inhibitors (ACEi): Enalapril, lisinopril (reduce afterload and remodeling).
- Angiotensin Receptor Blockers (ARB): Valsartan, losartan (alternative to ACEi).
- Sacubitril/Valsartan (ARNI): Superior to ACEi in HFrEF.

Advanced Pharmacologic Therapy

Other Therapies

- Mineralocorticoid Receptor Antagonists (MRA): Spironolactone, eplerenone (reduce fibrosis and mortality).
- **SGLT2 Inhibitors (SGLT2i)**: Empagliflozin, dapagliflozin (improve outcomes in HFrEF and HFpEF).